Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com -- Sana Biotechnology Inc (NASDAQ:SANA) stock plunged 26.7% after the cell engineering company announced the pricing of its underwritten public offering.
The company has priced an offering of 20,895,522 shares of common stock at $3.35 per share, along with pre-funded warrants to purchase 1,492,537 shares at $3.3499 per warrant for certain investors. The gross proceeds from the offering are expected to be approximately $75.0 million before deducting underwriting discounts and commissions and other expenses.
Sana has also granted the underwriters a 30-day option to purchase up to an additional 3,358,208 shares. The offering is expected to close on or about August 8, 2025, subject to customary closing conditions.
Morgan Stanley (NYSE:MS), Goldman Sachs & Co (NYSE:GS). LLC, BofA Securities, and TD Cowen are serving as joint book-running managers for the offering.
The significant stock decline reflects investor reaction to the potential dilution from the new share issuance. At the announced price of $3.35 per share, the offering represents a substantial discount to recent trading levels, putting downward pressure on the stock.
Sana Biotechnology focuses on developing engineered cells for therapeutic applications, with its platform aimed at creating novel cell-based treatments for patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.